MCL Injury Medications in Personal Injury Cases: A Clinical Guide

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 6 min read

Medial collateral ligament (MCL) injuries from car accidents and falls require a structured medication protocol spanning weeks to months. Learn which drugs treat MCL sprains and tears, how prescribing patterns support documentation, and how a pharmacy lien covers every prescription at zero upfront cost.

A medial collateral ligament (MCL) injury is a sprain or tear of the ligament on the inner side of the knee, commonly caused by a direct lateral blow or twisting force during car accidents, pedestrian impacts, and slip-and-fall incidents. MCL injuries range from Grade I (mild stretch) to Grade III (complete rupture) and require a medication protocol that matches the severity and healing timeline.

• MCL injuries are among the most common knee ligament injuries in personal injury cases, frequently accompanying ACL tears and meniscus damage
• Medication management spans two to twelve weeks depending on grade, covering pain control, inflammation reduction, and muscle spasm relief
• A pharmacy lien through LienScripts captures the full prescription record at zero upfront cost, creating objective documentation for settlement
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "MCL injury medication records demonstrate both the severity and the recovery timeline that attorneys need for demand packages"

How MCL Injuries Occur in Trauma

The MCL stabilizes the knee against valgus (inward-buckling) forces. In motor vehicle collisions, the dashboard or door panel can strike the outer knee, driving it inward and stretching or tearing the MCL. Pedestrians struck by vehicles frequently sustain MCL injuries when the bumper contacts the lateral knee. Slip-and-fall accidents produce MCL tears when the foot plants and the knee buckles inward on impact.

MCL injuries are graded by severity:

• Grade I — microscopic fiber tearing with intact ligament integrity. Pain and tenderness on the inner knee, minimal instability.
• Grade II — partial tear with moderate laxity. Significant swelling, difficulty bearing weight, and pain with valgus stress.
• Grade III — complete rupture. Gross instability, often accompanied by ACL or meniscus injury requiring surgical evaluation.

Acute Phase Medications (Weeks 1-3)

The initial treatment period focuses on controlling pain and inflammation while the ligament begins healing.

NSAIDs are the first-line pharmacologic intervention. Naproxen, ibuprofen, meloxicam, or celecoxib reduce both pain and the inflammatory cascade that drives swelling. For Grade II and III injuries, prescription-strength NSAIDs are typically preferred over over-the-counter doses because the inflammatory burden is substantial.

Acetaminophen is used as a scheduled adjunct, particularly for patients who cannot tolerate NSAIDs due to gastrointestinal risk or renal concerns. Around-the-clock acetaminophen provides baseline analgesia without anti-inflammatory effects.

Short-course opioids may be prescribed for Grade II and III MCL injuries during the first five to ten days, particularly when pain prevents sleep or early range-of-motion exercises. Hydrocodone/acetaminophen or tramadol are the most common choices for short-term use.

Muscle relaxants — cyclobenzaprine, tizanidine, or methocarbamol — address the protective muscle guarding that develops around the injured knee. The quadriceps and hamstrings reflexively spasm to limit motion, which increases pain and can impede early rehabilitation. Nighttime dosing improves sleep quality while reducing spasm.

Topical agents provide localized relief without systemic exposure. Diclofenac gel applied directly over the medial knee delivers anti-inflammatory medication to the injury site. Lidocaine patches reduce localized pain and are especially useful during the transition from acute rest to early physical therapy.

Rehabilitation Phase Medications (Weeks 3-8)

As physical therapy begins, medication needs shift from acute pain control toward managing activity-related inflammation and supporting progressive loading of the healing ligament.

As-needed NSAIDs remain the mainstay during rehabilitation. Each PT session — particularly those involving resistance exercises, lateral movement drills, and proprioception training — can provoke transient swelling that responds to anti-inflammatory medication.

Topical diclofenac gel becomes increasingly useful during this phase because it allows targeted treatment of the medial knee without the gastrointestinal burden of daily oral NSAIDs. Patients can apply it before and after PT sessions.

Muscle relaxants at bedtime continue for patients experiencing nocturnal cramping or spasm. Aggressive quadriceps strengthening during the day commonly triggers nighttime muscle irritability that disrupts sleep and impedes recovery.

For Grade III injuries managed non-operatively, or those with concurrent meniscal or ACL involvement, gabapentin or pregabalin may be introduced if neuropathic symptoms develop — burning, tingling, or electric sensations along the medial knee or inner leg. These symptoms suggest involvement of the infrapatellar branch of the saphenous nerve, which runs directly over the MCL.

Return-to-Activity Phase (Weeks 8-12+)

In the final recovery phase, medication use tapers but does not always disappear entirely.

Intermittent NSAID use continues for activity-related flares, particularly during return-to-sport or return-to-work activities that stress the knee. Some patients require periodic anti-inflammatory coverage for months after the initial injury, especially with Grade III tears.

Topical agents remain a low-risk option for managing residual discomfort during progressive activity loading. Many patients prefer continued use of diclofenac gel or lidocaine patches over oral medications at this stage.

Documentation Value of the MCL Medication Record

A complete pharmacy record spanning several weeks to months provides objective evidence that directly supports the personal injury claim:

• Duration of treatment demonstrates the injury was not trivial — a multi-week or multi-month prescription record refutes defense arguments that the MCL sprain resolved quickly
• Multiple drug classes (NSAIDs, muscle relaxants, topical agents, and potentially opioids or neuropathic agents) reflect multidimensional suffering
• Prescribing transitions from acute medications to rehabilitation-phase agents show medically supervised progression through recovery stages
• Fill frequency and consistency document ongoing compliance with treatment, which strengthens the plaintiff's credibility

When the LienScripts platform manages the pharmacy lien, every prescription fill is captured with timestamps, prescriber information, and drug details. This record integrates into the demand package alongside clinical notes and imaging.

Setting Up a Pharmacy Lien for MCL Treatment

The process begins when the treating physician or personal injury attorney contacts LienScripts to establish the lien agreement. All prescriptions related to the MCL injury are then filled through the lien at no cost to the patient. The lien is satisfied from settlement proceeds once the case resolves.

Related Resources

• ACL Surgery Medications on a Pharmacy Lien
• Knee Injury Without Surgery: Medications on a Pharmacy Lien
• Meloxicam for Knee Injury After an Accident
• Cyclobenzaprine After a Rear-End Collision